Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
SchizophreniaMental DisorderNervous System Diseases
Interventions
DRUG

Aripiprazole, OPC-14597

5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle

Trial Locations (11)

19139

CRI Lifetree, Philadelphia

20016

Comprehensive Clinical Development, Washington D.C.

30308

Atlanta Center for Medical Research, Atlanta

33308

Scientific Clinical Research, Inc., Fort Lauderdale

34748

Compass Research North, LLC, Leesburg

63118

St. Louis Clinical Trials, St Louis

78754

Community Clinical Research, Inc., Austin

90703

Comprehensive Clinical Development, Cerritos

92101

CNRI-San Diego, San Diego

92845

Collaborative Neuroscience Network, Inc., Garden Grove

08053

CRI Lifetree, Marlton

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01909466 - Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter